



Financial Tear Sheet

CORPORATE PROFILE

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

PRIMARY IR CONTACT

RussoPartners/LLC

Alex Fudukidis

Phone: (646) 942-5632

E-mail:

alex.fudukidis@russopartnersllc.com

STOCK PERFORMANCE

ONS (Share)

| | |
|----------------|--------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$0.99 |
| Change (%) | 0.00 (0.00%) |
| Volume | 89,170 |
| Today's Open | \$0.98 |
| Previous Close | \$0.99 |
| Intraday High | \$1.03 |
| Intraday Low | \$0.97 |
| 52 Week High | \$5.49 |
| 52 Week Low | \$0.95 |

Data as of 07/24/17 4:00 p.m. ET



LATEST NEWS

June 01, 2017

[Oncobiologics Closes On Final Portion Of \\$15 Million Senior Secured Note And Warrant Offering](#)

May 09, 2017

[Oncobiologics To Present At The World Biosimilar Congress 2017](#)

April 17, 2017

[Oncobiologics Secures Additional Funding](#)

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

| Filing Date | Form |
|-------------|-------|
| 07/06/17 | 8-K |
| 06/15/17 | 8-K |
| 05/16/17 | 424B3 |
| 05/16/17 | 424B3 |

Data provided by Nasdaq. Minimum 15 minutes delayed.